GLP-1 RAs in Patients With Polycystic Ovarian Syndrome (PCOS)
Status:
Enrolling by invitation
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to
15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation
disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other
metabolic abnormalities. Visceral fat dysfunction is an important factor in the onset of
PCOS. GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to
improving blood sugar control, weight loss and appetite suppression, and reducing
cardiovascular risk. The purpose of this study was to compare whether the combined treatment
of GLP-1 receptor agonists and calorie restrict diet reduced more visceral fat of
overweight/obese patients with PCOS at the same weight loss (7%) compared with calorie
restrict diet alone.